{"id":245159,"date":"2023-12-31T22:16:28","date_gmt":"2024-01-01T04:16:28","guid":{"rendered":"https:\/\/cannabisindustrylawyer.com\/?p=245159"},"modified":"2025-06-15T10:28:42","modified_gmt":"2025-06-15T16:28:42","slug":"what-does-schedule-iii-cannabis-mean","status":"publish","type":"post","link":"https:\/\/cannabisindustrylawyer.com\/what-does-schedule-iii-cannabis-mean\/","title":{"rendered":"Impacts and Benefits of Schedule III Cannabis"},"content":{"rendered":"
\n
\n
\n

In October of 2022, President Joe Biden directed the Attorney General and Health and Human Services (HHS) to evaluate the current Schedule I status of cannabis, called marijuana under the Federal Controlled Substances Act. This directive aimed to reevaluate the classification of cannabis and potentially move it from Schedule I to Schedule III.<\/span><\/strong><\/p>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n
\n

\"HHSOn August 29th, 2023, the HHS applied an 8-factor test under Section 811 of the CSA and sent its findings to the DEA. This comprehensive evaluation process involved assessing various elements of cannabis, including its potential for abuse, scientific evidence of its pharmacological effects, current scientific knowledge, history and pattern of abuse, risk to public health, potential for dependence, and its relation to other controlled substances.<\/span><\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n
\n

Based on the evaluation, the HHS recommended that cannabis be moved to Schedule III. This recommendation sets in motion a series of events under the Controlled Substances Act. The next steps include the initiation of a new rule or amendment, publication of an advance notice of proposed rulemaking (ANPRM) to seek public input, publication of a notice of proposed rulemaking (NPRM) with specific changes and analysis, a public comment period, review of public comments, publication of a final rule, and the possibility of judicial review.<\/span><\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n
\n

While the Attorney General has not yet announced a date for publishing an ANPRM on rescheduling cannabis, the Department of Justice has expressed its commitment to reviewing the classification based on the latest scientific evidence. It is important to stay updated on these developments as they unfold.<\/span><\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n
\n

Once a final rule is published, the effective date of the rescheduling will generally be no less than thirty days after the date of publication in the Federal Register. This means that if the proposed rule is published and allows for a 60-day comment period, the rescheduling of cannabis to Schedule III could potentially happen within a matter of months.\u00a0 Maybe a new federal cannabis license<\/a> is on the horizon.\u00a0<\/span><\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n
\n

However, it’s important to note that even with the rescheduling to Schedule III, cannabis will still be subject to certain regulations and restrictions. International law, specifically the Single Convention on Narcotic Drugs treaty, which the US agreed to in 1961 and incorporated into the CSA in 1970, prevents the complete removal of cannabis from the controlled substance schedules. This means that while there may be changes in the scheduling, cannabis will not be completely legalized due to international legal obligations.<\/span><\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n

Schedule III Cannabis Defined<\/span><\/span><\/h2>\n<\/div>\n<\/div>\n
\n
\n
\n
<\/div>\n

In the pharmacologic lexicon, <\/span><\/span>Schedule III<\/strong><\/span><\/span><\/a> substances are classified under the Controlled Substances Act (CSA) as drugs with a moderate to low potential for physical and psychological dependence. Cannabis assigned to this category is recognized for possessing legitimate medical applications, albeit with less restrictive regulatory measures than Schedules I and II drugs. Unlike its Schedule I counterparts, Schedule III cannabis is acknowledged for its therapeutic benefits, and though subject to federal oversight, is granted a conditional acceptance for medical use, providing a nuanced landscape for research and practice.<\/span><\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n

Classification Criteria<\/span><\/span><\/h3>\n<\/div>\n<\/div>\n
\n
\n
\n

Schedule III classification hinges on a balance between recognized medical use and the potential for dependence.<\/span><\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n

Cannabis with lower dependence risk can qualify for Schedule III, enhancing therapeutic research opportunities.<\/span><\/span><\/p><\/blockquote>\n<\/div>\n<\/div>\n

\n
\n
\n

A substance must exhibit a moderate to low risk of dependence, both physical and psychological, to be deemed Schedule III.<\/span><\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n
\n

Substances classified under Schedule III are subject to comprehensive regulatory control, ensuring safety in their legal medical application and distribution.<\/span><\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n

Comparing Schedules I, II, and III<\/span><\/span><\/h3>\n<\/div>\n<\/div>\n
\n
\n
\n

The classification into Schedules I, II, and III marks distinct legal and regulatory implications for substances.<\/span><\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n
    \n
  1. \n
    Schedule I<\/strong><\/span><\/span> substances are deemed to have high potential for abuse, no currently accepted medical use in the U.S., and a lack of accepted safety for use under medical supervision, thus are strictly prohibited.<\/span><\/span><\/div>\n<\/li>\n
  2. \n
    Schedule II<\/strong><\/span><\/span> substances also have a high potential for abuse but have some accepted medical uses with severe restrictions due to their addictive qualities.<\/span><\/span><\/div>\n<\/li>\n
  3. \n
    Schedule III<\/strong><\/span><\/span> substances, by contrast, have a lower potential for abuse relative to Schedule I and II substances and are considered to have currently accepted medical use in treatment in the U.S. (IRC Section 280E does not apply).<\/span><\/span>Navigating from Schedule I to Schedule III denotes a transition from a strictly regulated to a more accessible status for medical research and patient care.<\/span><\/span><\/div>\n<\/li>\n<\/ol>\n<\/div>\n<\/div>\n
    \n
    \n
    \n

    The appropriate scheduling of cannabis influences not only its legal accessibility but also research, medical, and commercial opportunities.<\/span><\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n

    \n
    \n

    Implications for Medical Use<\/span><\/span><\/h2>\n<\/div>\n<\/div>\n
    \n
    \n
    \n
    <\/div>\n

    With cannabis categorized under <\/span><\/span>Schedule III<\/strong><\/span><\/span>, its acknowledged medical utility opens avenues for practitioners to prescribe it within a regulated framework, enhancing its integration into traditional pharmacopeia. Indeed, this reclassification signifies acknowledgment of its therapeutic potential, easing the process for healthcare providers to incorporate cannabis-based treatments into patient care plans.<\/span><\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n

    \n
    \n
    \n

    The reclassification of cannabis illuminates a path toward broader clinical trials and research, enabling a more robust understanding of its efficacy and safety across different medical conditions. Evidently, this shift carries profound implications for the advancement of cannabinoid science and patient access to novel therapies.<\/span><\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n

    \n
    \n

    Research Opportunities<\/span><\/span><\/h3>\n<\/div>\n<\/div>\n
    \n
    \n
    \n
    <\/div>\n

    Schedule III classification of cannabis significantly broadens the scope for scientific study and medical research.<\/span><\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n

    \n
    \n